Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.

Teva Pharmaceuticals, in partnership with Direct Relief and the National Association of Free and Charitable Clinics, has launched a $2 million program to enhance access to mental health care for underserved populations. The initiative will provide funding over two years to free clinics while donating generic medications for anxiety and depression. Initially focused on Florida, New Jersey, and California, this program aims to address health equity issues exacerbated by the COVID-19 pandemic, supporting clinics to provide necessary resources and care for uninsured patients.

Teva Pharmaceuticals has settled opioid-related claims with the Attorney General of West Virginia, agreeing to pay $75 million over 15 years and provide $27 million in the generic version of Narcan over 10 years. The settlement also includes $8 million for attorney fees. While this settlement advances efforts to address opioid addiction, it is not an admission of liability. Teva is negotiating a national settlement to further address ongoing litigation.

Teva Pharmaceuticals has released new data highlighting the efficacy and safety of AUSTEDO in postmenopausal women with tardive dyskinesia (TD) over a three-year open-label extension study. AUSTEDO showed significant improvements in motor symptoms, with 68% of patients experiencing notable improvements by Week 145. Additionally, the psychological, social, and physical impacts of TD were examined through surveys of patients and caregivers, revealing considerable negative effects on daily life. These findings will be presented at the 2022 American Psychiatric Association Annual Meeting in New Orleans.

Teva Pharmaceutical has received approval from the UK Medicines & Healthcare Regulatory Agency (MHRA) for its biosimilar Ongavia^® (ranibizumab), targeting wet age-related macular degeneration (AMD) and other eye diseases. Ongavia^® is the first ophthalmology biosimilar to be commercialized by Teva in Europe. The approval allows treatment for visual impairment-related conditions, potentially enhancing patient access to affordable therapies. Teva's partnership with Bioeq AG aims to extend Ongavia^®'s commercialization throughout Europe.

Teva Pharmaceuticals announced four data presentations regarding AUSTEDO (deutetrabenazine) and TV-46000, presented at the American Psychiatric Association Annual Meeting from May 21-25, 2022. Key studies include long-term safety and efficacy of AUSTEDO for tardive dyskinesia, and a new copolymer technology for TV-46000 targeting schizophrenia. Teva will also host educational sessions on mental health's social determinants and the clinical benefits of long-acting injectables in schizophrenia treatment. The data reflects Teva's commitment to addressing mental health needs.

Teva Pharmaceuticals announced findings from a clinical study on SABA use among asthma patients, presented at the ATS 2022 Annual Meeting. The study revealed significant SABA overuse, with nearly one-third of patients making over 138 inhalations in 12 weeks. Key findings indicated that 89% of patients exceeded the consensus threshold for SABA use, suggesting a potential risk for asthma exacerbation. The ProAir Digihaler digital inhaler was highlighted as a tool to help healthcare providers make informed treatment decisions based on real-time patient data.

Teva Canada Limited has announced the public formulary coverage for AJOVY® (fremanezumab) in several provinces including Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, enhancing accessibility for migraine patients across Canada. AJOVY® is indicated for adults with at least four migraine days monthly. This development follows similar coverage announcements in Alberta, Saskatchewan, and Québec. The increased availability of AJOVY® is expected to improve the quality of life for many Canadians suffering from migraines.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will present findings at the ATS 2022 Annual Meeting held from May 13-18, 2022, in San Francisco. These findings focus on the use of short-acting beta agonists (SABA) in asthma patients, utilizing data from the ProAir Digihaler. This analysis applies clinical usage thresholds from independent experts to objective patient data, marking the first such study of its kind. The research highlights the potential for digital inhalers to enhance asthma management and patient outcomes.